Neurona Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for NRTX-1001 in Focal Epilepsy

Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for disorders of the nervous system, today announced that the U.S Food and Drug Administration (FDA) has granted the company’s lead product candidate, NRTX-1001, the RMAT expedited program designation for drug-resistant mesial temporal lobe epilepsy (MTLE).

Cory Nicholas, PhD, is the lead UCSF inventor, Neurona’s Co-Founder and Chief Executive Officer. We congratulate his success.